Edition 3542
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Scientific Committee on Vaccine Preventable Diseases and Scientific Committee on Emerging and Zoonotic Diseases
Scientific Committee on Emerging and Zoonotic Disease and Scientific Committee on Vaccine Preventable Diseases Consensus Interim Recommendations on the Use of COVID-19 Vaccines in Hong Kong (As of Jan 7, 2021) Introduction The ongoing COVID-19 pandemic causes a significant disease burden worldwide. In Hong Kong, cases and outbreaks continue to be reported. To reduce the impacts of COVID-19 on health and society, vaccines against COVID-19 is considered an important public health tool for containing the pandemic in the medium and long term. On 7 January 2021, the Scientific Committee on Emerging and Zoonotic Diseases (SCEZD), the Scientific Committee on Vaccine Preventable Diseases (SCVPD), and the Expert Advisory Panel to Chief Executive (EAP) reviewed the latest scientific evidence on the epidemiology and clinical features of COVID-19, published data on the COVID- 19 vaccines be procured by the Hong Kong SAR Government, local data as well as overseas recommendations/practices, and provides recommendations on the population groups and circumstances for the use of COVID-19 vaccines in Hong Kong. COVID-19 Vaccines 2. At the meeting held on 13 August 2020, the joint SCEZD and SCVPD together with the EAP reviewed the then scientific development of COVID 19 vaccines and prioritization of target groups for COVID 19 vaccines in Hong Kong. The meeting recommended that vaccine procurement would be aimed at the whole Hong Kong population in the long run. In anticipation of a limited supply at the early stage when vaccines are available, a phased approach has to be taken with certain priority groups of the local population identified to be vaccinated first, in order to reduce morbidity and mortality and maintain essential services. -
Orçamento 2021
DEMONSTRAÇÕES PREVISIONAIS ORÇAMENTO 2021 PLANO ORÇAMENTAL PLURIANUAL 2021 | 2025 DEMONSTRAÇÕES FINANCEIRAS PREVISIONAIS 2021 Novembro de 2020 ORÇAMENTO 2021 DA CIDADE DE LISBOA ÍNDICE PARTE I – SUMÁRIO EXECUTIVO …………………………………………………………….………………3 1. NOTA DE ABERTURA ………………………………….………………………………………………………4 2. ENQUADRAMENTO DO PROCESSO ORÇAMENTAL ….……………………….……………………...7 2.1. CONTEXTO MACROECONÓMICO ..………..……….……….…………………….……………………..7 2.2. FATORES EXÓGENOS AO MUNICÍPIO DE LISBOA ……………………………….……………….9 2.3. EVOLUÇÃO RECENTE DO MUNICÍPIO DE LISBOA ………………..….…………………………….11 3. ORIENTAÇÕES TÉCNICAS DA CONSTRUÇÃO DAS DEMONSTRAÇÕES PREVISIONAIS ……....14 4. ORIENTAÇÕES ESTRATÉGICAS DA POLÍTICA ORÇAMENTAL ……………………………………18 4.1. RESPONDER À EMERGÊNCIA …………………………………………………………………...18 4.2. MANTER FOCO NO INVESTIMENTO ……………………………………………………………………20 4.2.1. HABITAÇÃO ………………………………………………………………………………………………..20 4.2.1. MOBILIDADE ……………………………………………………………………………………………….23 4.2.3. CIDADE SUSTENTÁVEL – AMBIENTAL, SOCIAL E ECONÓMICA …………………………….…..24 4.2.4. EIXOS DO PROGRAMA DE GOVERNO DA CIDADE - SÍNTESE …………………………….....29 4.3. CONTAS SUSTENTÁVEIS E RIGOROSAS ………………………………….…………………….....30 4.3.1. RECEITA ……………………………………………………………………………………………..........31 4.3.2. DESPESA ………………………………………………………………………………………………….33 5. MELHORES CONDIÇÕES DE TRABALHO, MAIOR RESPOSTA À CIDADE ……………..………...36 PARTE II – REGULAMENTO DO ORÇAMENTO …….……………………………………………………...39 PARTE III – SÍNTESES DO ORÇAMENTO …………………………….……………………...................…65 QUADRO 1. RESUMO DO ORÇAMENTO DE 2021 ...............................................................................66 -
Not Just Another Crapshoot Development: the Challenges and Opportunities of Modelling After Las Vegas and Macao As an Econo
Khiatani Bandung J of Global South (2015) 1:8 DOI 10.1186/s40728-015-0024-8 RESEARCH Open Access Not just another crapshoot development: the challenges and opportunities of modelling after Las Vegas and Macao as an economic development strategy in the 21st century Paul Vinod Khiatani* *Correspondence: [email protected] Abstract Department of Applied Recent decades highlight an extraordinary growth of casino gambling all over the Social Sciences, City University of Hong Kong, 83 world. In the race to build casino-cities, particularly to reap economic and social Tat Chee Ave, Kowloon, Hong benefits, most aspirers look to replicate the development models of the most famous Kong casino-cities known to date, Las Vegas and Macao. Countries that have modelled after the aforementioned casino-cities have had mix results of success; e.g., Singapore, which followed Macao, yielded considerable success, while other states of the US which modelled Las Vegas, such as Atlantic City, did not have as much luck. In this respect, the countries adhere to the words of the wise; “Standing on the shoulders of the giants”. Yet, perhaps explaining why no country can really replicate the successful development experiences of Las Vegas and Macao, most countries fail to see beyond the glitz and glamor to recognize the key challenges and opportunities that helped make Las Vegas and Macao; e.g., with respect to the presence of domestic organized crime groups. This paper delves deep into identifying the key actors and circumstances that made the aforementioned cities what they are today, elucidating the integral development strategies used during their formative years. -
第十三屆 Asian Gaming
inside asian gaming NOV #173 | 45 MOP 2020年 11月 THE 13TH第十三屆 ASIAN GAMING 2020 www.asgam.com NOV CONTENTS2020年 11月 內容 Cover : 封面 Inside Asian Gaming COLUMNISTS 12 Breakfast Briefs 126 How to set up for IR success Former Victorian gaming regulator Peter Cohen discusses the effectiveness of three key methodologies commonly used in the development of new IRs. TECH TALK 136 Shuffle up and deal Scientific Games has added key security and efficiency THE ASIAN GAMING POWER 50 enhancements to its hugely popular ShuffleStar continuous card shuffler. 26 Top of the world Inside Asian Gaming celebrates another eventful year for Asian gaming with the industry’s definitive list of the 50 most powerful people in Asia. TECH TALK 38 Meet the panel! 140 Transcendence Jumbo is aiming to transcend the limitations of the Perhaps the only job tougher than compiling the Asian Gaming COVID-19 pandemic by bringing energy to the market via Power 50 was assembling a panel qualified to choose them. its new Long Yi Fa slot machine series. 48 Meet the 2020 Asian Gaming Power 50! And here it is! This year’s list of the men and women who truly drove the industry forward in 2020. TECH TALK The next 5 114 Bridging the gap These five are the people knocking on the door of the Power 50 144 and those we currently consider the most likely new entrants Dallmeier’s Konrad Hechtbauer explains how casinos can next year. use smart, AI-infused video-based technologies to take the next step forward in moving from analogue to digital 118 Ones to watch processes. -
Immunogenicity and Safety of a Third Dose, and Immune Persistence Of
medRxiv preprint doi: https://doi.org/10.1101/2021.07.23.21261026; this version posted July 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. 1 Immunogenicity and safety of a third dose, and immune persistence of 2 CoronaVac vaccine in healthy adults aged 18-59 years: interim results 3 from a double-blind, randomized, placebo-controlled phase 2 clinical 4 trial 5 6 Hongxing Pan MSc1*, Qianhui Wu MPH2*, Gang Zeng Ph.D.3*, Juan Yang Ph.D.1, Deyu 7 Jiang MSc4, Xiaowei Deng MSc2, Kai Chu MSc1, Wen Zheng BSc2, Fengcai Zhu M.D.5†, 8 Hongjie Yu M.D. Ph.D.2,6,7†, Weidong Yin MBA8† 9 10 Affiliations 11 1. Vaccine Evaluation Institute, Jiangsu Provincial Center for Disease Control and 12 Prevention, Nanjing, China 13 2. School of Public Health, Fudan University, Key Laboratory of Public Health Safety, 14 Ministry of Education, Shanghai, China 15 3. Clinical Research Department, Sinovac Biotech Co., Ltd., Beijing, China 16 4. Covid-19 Vaccine Department, Sinovac Life Sciences Co., Ltd., Beijing, China 17 5. Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China 18 6. Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, 19 Shanghai, China 20 7. Department of Infectious Diseases, Huashan Hospital, Fudan University, 21 Shanghai, China 22 8. Sinovac Biotech Co., Ltd., Beijing, China NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. -
Casino Boss Francis Lui Won Big in Macau, but His Next
IT DIDN’T QUITE WORK OUT THAT WAY. A partnership with an American casino operator fi zzled, so after running a couple of card clubs in other peo- ple’s hotels, his family’s irm, Galaxy Entertainment Group, built one of Macau’s new glittering casinos BY RUSSELL PEARLMAN in 2006. That and building two other incredibly successful casinos in Macau transformed Lui, 62, from the ambitious son of a wealthy Hong Kong con- struction magnate into one of the world’s richest men. In turn, Lui helped transform Macau—which over the past several hundred years has been, in turn, a waystation for refugees fl eeing the Mongols, a bustling Portuguese-run trading colony, a haven for CASINO BOSS early-20th-century gangsters and a neutral port in the storm of World War II—into its latest incarnation: the world’s biggest betting parlor. Gamblers drop more than FRANCIS LUI WON BIG $28 billion a year betting at Macau’s casinos. Las Vegas doesn’t even get one-quarter of that. But instead of sitting back and enjoying Macau’s current form, he’s at the forefront of trying to reinvent the area yet IN MACAU, BUT HIS again. He’s making a multibillion-dollar bet that Macau’s next reinvention won’t involve much gambling at all. Over the next few years, Galaxy wants to add NEXT BET BARELY 10.7 million square feet of space to its existing Galaxy Macau resort, nearly doubling its size. It potentially will include a convention center, a concert venue with INVOLVES GAMBLING. -
COVID-19: China Medical Supply Chains and Broader Trade Issues
COVID-19: China Medical Supply Chains and Broader Trade Issues Updated December 23, 2020 Congressional Research Service https://crsreports.congress.gov R46304 SUMMARY R46304 COVID-19: China Medical Supply Chains and December 23, 2020 Broader Trade Issues Karen M. Sutter, The outbreak of Coronavirus Disease 2019 (COVID-19), first in China, and then Coordinator globally, including in the United States, has drawn attention to the ways in which the Specialist in Asian Trade U.S. economy depends on manufacturing and supply chains based in China. This report and Finance aims to assess current developments and identify immediate and longer range China trade issues for Congress. Andres B. Schwarzenberg Analyst in International An area of particular concern to Congress has been U.S. shortages in medical supplies— Trade and Finance including personal protective equipment (PPE) and pharmaceuticals—as the United States stepped up efforts to contain the COVID-19 pandemic with limited domestic Michael D. Sutherland stockpiles and insufficient U.S. industrial capacity. Because of China’s role as a global Analyst in International supplier of PPE, medical devices, antibiotics, and active pharmaceutical ingredients, Trade and Finance reduced exports from China led to shortages of critical medical supplies in the United States. Exacerbating the situation, in early February 2020, the Chinese government nationalized control of the production and distribution of medical supplies in China— directing all production for domestic use—and directed the bureaucracy and Chinese industry to secure supplies from the global market. Once past the initial peak of its COVID-19 outbreak, the Chinese government appears to have prioritized certain countries and selectively released some medical supplies for overseas delivery. -
WHO Survey on the Sharing of Genetic Sequence Data Of
WHO Survey on the Sharing of Genetic Sequence Data of Influenza Viruses with Human Pandemic Potential Results and Analysis of data received 27 April 2016 Table of Contents Acknowledgement .................................................................................................................................. 3 Acronyms ................................................................................................................................................ 4 Executive Summary ................................................................................................................................. 5 Background ............................................................................................................................................. 8 Methodology Summary .......................................................................................................................... 9 IVPP GSD Sharing in Numbers (as of October 2014)............................................................................. 10 Survey Results ....................................................................................................................................... 11 1. Mechanisms for sharing of IVPP GSD........................................................................................ 11 2. Ease of sharing .......................................................................................................................... 13 3. Systematic sharing ................................................................................................................... -
Dentons Flashpoint Daily Global Situation Report
Dentons Flashpoint Daily Global Situation Report December 14, 2020 Global Situation Update: December 14, 2020 KEY TAKEAWAYS The US orders First COVID-19 emergency action The UN calls on vaccines to be after huge cyber every country administered in the security breach to declare a US and Canada involving the “climate emergency.” today. SolarWinds’ Orion platform. Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same. Global Globally, confirmed coronavirus cases surpassed 72 million infections and 1.6 million deaths. • Secretary-General Guterres called on every • German biotech firm CureVac has enrolled the country to declare a “climate emergency” as first participant for a Phase 2b/3 clinical trial world leaders marking the fifth anniversary of of its COVID-19 vaccine candidate, expected the Paris climate accord made mostly to include more than 35,000 participants in incremental pledges relative to the scale of the Europe and Latin America. crisis. • Peru suspended clinical trials of a Chinese Sinopharm Covid-19 vaccine after one of the volunteers involved in the program suffered a “serious adverse event”. Note: This report is based on sources and information deemed to be true and reliable, but Dentons makes no representations to same. Global Over the past week, the global curve for new cases continued to flatten, while topping 72 million. One week ago, the count was 67 million. The US continues to be the global leader for new infections, reporting more than 200,000 new cases for most of last week. Turkey has become the new global hotspot, with new cases doubling in eight days to over 1.8 million. -
Stanley Ho, 'King of Gambling' Who Built Macau, Dies at 98
5/27/2020 Stanley Ho, ‘King of Gambling’ Who Built Macau, Dies at 98 - Bloomberg Business Stanley Ho, ‘King of Gambling’ Who Built Macau, Dies at 98 By Vinicy Chan and Daniela Wei May 26, 2020, 1:58 PM GMT+8 Updated on May 26, 2020, 3:44 PM GMT+8 Ho transformed Chinese island Macau into ‘Las Vegas of Asia’ SJM shares rise on optimism descendants have plan in place 1:18 Macau Casino Tycoon Stanley Ho Dies at 98 Stanley Ho, a onetime kerosene trader who built a casino empire in Macau that propelled the Chinese island past Las Vegas as the world’s biggest gambling hub, has died at age 98, members of his family said. Known as the King of Gambling, Ho dominated gaming in the former Portuguese colony after winning a monopoly license in 1961. His SJM Holdings Ltd. flourished as China’s economic opening created a flood of new wealth in a country with a passion for gambling. SJM now controls 20 casinos on an island of about 10 square miles. “Our four families stand united in our grief and respect for his legendary accomplishments, everything he has done in life for Hong Kong, with Hong Kong, Macau and all his charitable donations,” one of his daughters said outside Hong Kong Sanatorium & Hospital. https://www.bloomberg.com/news/articles/2020-05-26/stanley-ho-king-of-gambling-who-built-macau-dies-at-98 1/5 5/27/2020 Stanley Ho, ‘King of Gambling’ Who Built Macau, Dies at 98 - Bloomberg SJM shares rallied as investors were optimistic that the four branches of Ho’s descendants -- he had 17 children with four women -- have a plan in place following a 2019 alliance, despite earlier feuding. -
Annual Report DBX ETF Trust
May 31, 2021 Annual Report DBX ETF Trust Xtrackers Harvest CSI 300 China A-Shares ETF (ASHR) Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF (ASHS) Xtrackers MSCI All China Equity ETF (CN) Xtrackers MSCI China A Inclusion Equity ETF (ASHX) DBX ETF Trust Table of Contents Page Shareholder Letter ....................................................................... 1 Management’s Discussion of Fund Performance ............................................. 3 Performance Summary Xtrackers Harvest CSI 300 China A-Shares ETF ........................................... 6 Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF .................................. 8 Xtrackers MSCI All China Equity ETF .................................................... 10 Xtrackers MSCI China A Inclusion Equity ETF ............................................ 12 Fees and Expenses ....................................................................... 14 Schedule of Investments Xtrackers Harvest CSI 300 China A-Shares ETF ........................................... 15 Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF .................................. 20 Xtrackers MSCI All China Equity ETF .................................................... 28 Xtrackers MSCI China A Inclusion Equity ETF ............................................ 33 Statements of Assets and Liabilities ........................................................ 42 Statements of Operations ................................................................. 43 Statements of Changes in Net -
Cansino Receives GMP Certificate for Convideciaž, COVID-19 Vaccine
CanSino receives GMP certificate for Convidecia™, COVID-19 vaccine 25 May 2021 | News | By BioSpectrum Bureau This certification signifies CanSinoBIO's readiness to enter more markets in Europe and globally CanSino Biologics Inc has announced that its recombinant novel coronavirus vaccine, (Adenovirus Type 5 Vector) (‘Ad5- nCoV’, trade name: Convidecia™), has been granted a good manufacturing practice (GMP) certificate by the Hungarian National Institute of Pharmacy and Nutrition (OGYÉI). The certification was issued on May 21, 2021 after a thorough inspection of CanSinoBIO's production of Convidecia™. The GMP certificate recognises that CanSinoBIO's manufacturing facilities and quality control system comply with the high production standards and guidelines required by the European Union (EU). The EU GMP certification is required to import COVID-19 vaccines into the European Union and is regarded as a recognition of leading industry standards by many authorities outside of the EU. This certification signifies CanSinoBIO's readiness to enter more markets in Europe and globally. CanSinoBIO opened a new vaccine production site in Tianjin, China, with the expectation to produce over 200 million doses of Convidecia™ per annum. It will continue to expand its manufacturing capacity by collaborating with other top-tier pharmaceutical companies in China, including Shanghai Pharmaceuticals Holding Co, Ltd, to better meet the growing global demand. In March 2021, CanSinoBIO started the phase I clinical trial of an inhaled version of Convidecia™ immediately after receiving the approval from the National Medical Products Administration of China, marking another milestone in bringing more acceptable, affordable, timely and mass immune protection to the global population and reducing the burden placed on healthcare systems and medial workers..